title: Antineoplastic effect of new boron compounds against leukemic cell lines and cells from leukemic patients.
abstract: Three new boron compounds, dihydroxy (oxybiguanido) boron (iii) hydrochloride monohydrate (HB), guanidine biboric acid adduct (GB) and hydroxosalicyl hydroxomato boron (iii) (SHB) were studied to observe their antineoplastic effect, if any. Leukemic cells isolated from acute lymphatic leukaemia (ALL) patients and chronic myeloid leukaemia patients (CML) and myeloid leukemia cell lines (HL 60 and U-937) showed cell growth inhibition after treatment with the boron compounds. MTT assay showed that the growth of metabolically active cells was inhibited by treatment with these drugs. The molecular mechanism by which SHB induced apoptosis in immature blast cells was also investigated by ladder formation in gel electrophoresis.
authors.affiliation: Chittaranjan National Cancer Institute, Kolkata, India.
authors.forename: N
authors.initials: N
authors.lastname: Murmu
authors.forename: P
authors.initials: P
authors.lastname: Ghosh
authors.forename: A
authors.initials: A
authors.lastname: Gomes
authors.forename: S
authors.initials: S
authors.lastname: Mitra
authors.forename: M
authors.initials: M
authors.lastname: Das
authors.forename: S E
authors.initials: SE
authors.lastname: Besra
authors.forename: J
authors.initials: J
authors.lastname: Majumdar
authors.forename: S
authors.initials: S
authors.lastname: Bhattacharya
authors.forename: P
authors.initials: P
authors.lastname: Sur
authors.forename: J R
authors.initials: JR
authors.lastname: Vedasiromoni
mesh_terms: D000208:Acute Disease; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001896:Boron Compounds / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D006146:Guanidines / Q000494:pharmacology; D018922:HL-60 Cells / Q000187:drug effects / Q000473:pathology; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D013778:Tetrazolium Salts; D013844:Thiazoles; D013936:Thymidine / Q000378:metabolism; D020298:U937 Cells / Q000187:drug effects / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001896:Boron Compounds; D006146:Guanidines; D013778:Tetrazolium Salts; D013844:Thiazoles; C121738:dihydroxy(oxybiguanido)boron (III); C117044:guanidine biboric acid adduct; C022616:thiazolyl blue; D013936:Thymidine